Efficacy and safety of bazedoxifene in postmenopausal Asian women
- First Online:
- 286 Downloads
This 6-month study examined the efficacy and safety of bazedoxifene 20 mg in postmenopausal Asian women. Bazedoxifene showed statistically significant improvements over placebo in bone mineral density at all skeletal sites evaluated. Bazedoxifene significantly reduced bone turnover and had favorable effects on lipid parameters. Bazedoxifene was safe and well tolerated.
This 6-month, randomized, double-blind, placebo-controlled phase 3 study conducted in China, Korea, and Taiwan evaluated the efficacy and safety of bazedoxifene in postmenopausal Asian women.
Generally, healthy postmenopausal Asian women (N = 487; mean age, 57.2 years; mean lumbar spine bone mineral density [BMD], −1.1) were randomized to daily therapy with bazedoxifene 20 mg or placebo; all subjects received daily supplemental calcium carbonate 600 mg. The changes from baseline in BMD at the lumbar spine (primary end point) and at other skeletal sites, bone turnover markers, and lipid parameters were evaluated at 6 months. Safety assessments included adverse event (AE) reporting and physical/gynecologic examination.
At 6 months, women who received bazedoxifene 20 mg had significantly greater BMD compared with those receiving placebo at the lumbar spine (0.41% vs −0.32%, P < 0.01), femoral neck (−0.08% vs −0.69%, P = 0.014), trochanter (0.50% vs −0.23%, P = 0.010), and total hip (−0.03% vs −0.77%, P < 0.001), respectively. Bazedoxifene 20 mg was also associated with significant differences from placebo in median percent reductions from baseline in serum C-telopeptide (−21.8%, P < 0.001) and osteocalcin (−12.9%, P < 0.001) levels and total (−5.0%, P < 0.001) and low-density lipoprotein cholesterol (−9.5%, P < 0.001) levels. The incidence of AEs was not different between subjects treated with bazedoxifene and those who received placebo.
Bazedoxifene was generally safe and effective in preventing bone loss in this short-term study of postmenopausal Asian women.
KeywordsBazedoxifene Bone mineral density Osteoporosis Postmenopausal Prevention SERMs
- 6.Wu XP, Liao EY, Zhang H, Dai RC, Shan PF, Cao XZ, Liu SP, Jiang Y (2004) Determination of age-specific bone mineral density and comparison of diagnosis and prevalence of primary osteoporosis in Chinese women based on both Chinese and World Health Organization criteria. J Bone Miner Metab 22:382–391PubMedGoogle Scholar
- 11.Hosking D, Chilvers CE, Christiansen C, Ravn P, Wasnich R, Ross P, McClung M, Balske A, Thompson D, Daley M, Yates AJ, for the Early Postmenopausal Intervention Cohort Study Group (1998) Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med 338:485–492CrossRefGoogle Scholar
- 13.Kung A, Chao HT, Huang KE, Need AG, Taechakraichana N, Loh FH, Gonzaga F, Sriram U, Ismail NM, Farooqu A, Rachman IA, Crans GG, Wong M, Thiebaud D (2003) Efficacy and safety of raloxifene 60 milligrams/day in postmenopausal Asian women. J Clin Endocrinol Metab 88:3130–3136CrossRefPubMedGoogle Scholar
- 14.Miller PD, Chines AA, Christiansen C, Hoeck HC, Kendler DL, Lewiecki EM, Woodson G, Levine AB, Constantine G, Delmas PD (2008) Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res 23:525–535CrossRefPubMedGoogle Scholar
- 15.Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta JR, de Villiers TJ, Constantine GD, Chines AA (2008) Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo- and active-controlled clinical trial. J Bone Miner Res 23:1923–1934CrossRefPubMedGoogle Scholar
- 20.Ravn P, Weiss SR, Rodriguez-Portales JA, McClung MR, Wasnich RD, Gilchrist NL, Sambrook P, Fogelman I, Krupa D, Yates AJ, Daifotis A, Fuleihan GE (2000) Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group. J Clin Endocrinol Metab 85:1492–1497CrossRefPubMedGoogle Scholar
- 21.Itabashi A, Ohta H, Ebede B, Constantine G, Chines AA (2008) A double-blind, placebo-controlled, dose-response study of bazedoxifene in Japanese postmenopausal women with osteoporosis. In: 2008 American Society for Bone and Mineral Research Abstract Book. Washington, DC: American Society for Bone and Mineral Research; 2008: 472. Abstract M391Google Scholar
- 27.Rice VM (2005) Strategies and issues for managing menopause-related symptoms in diverse populations: ethnic and racial diversity. Am J Med 118 Suppl:142–147Google Scholar
- 29.Neff MJ (2004) NAMS releases position statement on the treatment of vasomotor symptoms associated with menopause. Am Fam Physician 70:393–394, 396, 399Google Scholar
- 30.Sugimoto T, Itabashi A, Ohta H, Ochi H, Chines AA, Constantine G (2008) The safety profile of bazedoxifene in Japanese postmenopausal women with osteoporosis. In: 2008 American Society for Bone and Mineral Research Abstract Book. Washington, DC: American Society for Bone and Mineral Research; 2008: 471. Abstract M389Google Scholar
- 31.Ravn P, Hosking D, Thompson D, Cizza G, Wasnich RD, McClung M, Yates AJ, Bjarnason NH, Christiansen C (1999) Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 84:2363–2368CrossRefPubMedGoogle Scholar